Elevated serum concentration of interleukin-1 receptor antagonist (IL- 1ra) is correlated to interleukin-6 and to hypoalbuminemia in cachectic patients with colorectal cancer

被引：8

作者：

Shibata M. ^{[1
]}

Nagata Y. ^{[1
]}

Kimura T. ^{[1
]}

Kanou H. ^{[1
]}

Nezu T. ^{[1
]}

Takekawa M. ^{[1
]}

Fukuzawa M. ^{[1
]}

机构：

[1] First Department of Surgery, Nihon University, School of Medicine, Tokyo 173-0032, 30-1 Oyaguchi-kamimachi, Itabashi-ku

来源：

International Journal of Clinical Oncology | 2000年 / 5卷 / 2期

关键词：

Cachexia; Colorectal cancer; Interleukin-1 receptor antagonist; Interleukin-6;

D O I：

10.1007/s101470050101

中图分类号：

学科分类号：

摘要：

Background. The mechanisms leading to the development of cancer cachexia are still not well understood. Some important factors, including cytokines and growth factors, are involved, and recently, cytokines such as interleukin-1 and interleukin-6 have been reported to be involved as mediators of this disorder. Methods. In patients with colorectal cancer, serum concentrations of interleukin-1 receptor antagonist (IL-1ra) and interleukin-6 (IL-6) were measured by enzyme-linked immunosorbent assay (ELISA) and analyzed in relation to the patient's nutrition (in terms of albumin concentration [percentage of total protein] in the serum) and the tumor load. Results. The concentration of IL-1ra was significantly increased in cachectic patients compared with that in healthy volunteers and in the non-cachectic patients, and the concentration was correlated to the serum concentration of IL-6 and inversely correlated to the concentration of albumin (%). These concentrations, however, did not correlate to levels of tumor markers tested, ie, carcinoembryonic antigen (CEA) and carbohydrate antigen (CA)19-9. Conclusion. It was shown that the serum concentration of IL-1ra was a useful indicator for cancer cachexia and hypoalbuminemia; IL-1ra seems to be produced by immune-regulating host cells rather than by neoplastic cells.

引用

页码：116 / 120

页数：4

共 25 条

[1]

Tessitore L., Costelli P., Baccino F.M., Humoral mediation for cancer cachexia in tumour-bearing rats, Br J Cancer, 67, pp. 15-23, (1993)

[2]

Lawson D.H., Richmond A., Nixon D.W., Rudman D., Metabolic approaches to cancer cachexia, Annu Rev Nutr, 2, pp. 277-301, (1982)

[3]

Morrison S.D., Cancer cachexia, Influence of Tumor Development on the Host, pp. 176-213, (1989)

[4]

Dinarello C.A., Interleukin-1 and interleukin-1 antagonism, Blood, 77, pp. 1627-1652, (1991)

[5]

Arend W.P., Joslin F.G., Massoni R.J., Effects of immune complexes on production by human monocytes of interleukin-1 or an interleukin-1 inhibitor, J Immunol, 134, pp. 3868-3874, (1985)

[6]

Seckinger P., Lowenthal J.W., Williamson K., Et al., A urine inhibitor of interleukin-1 activity that blocks ligand binding, J Immunol, 139, pp. 1546-1554, (1987)

[7]

Eisenberg S.P., Evans R.J., Arend W.P., Et al., Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist, Nature, 343, pp. 341-342, (1990)

[8]

Dinarello C.A., Thompson R.C., Blocking of IL-1: Interleukin-1 receptor antagonist in vivo and in vitro, Immunol Today, 12, pp. 404-407, (1991)

[9]

Arend W.P., Interleukin-1 receptor antagonist. A new member of the interleukin-1 family, J Clin Invest, 88, pp. 1445-1452, (1991)

[10]

Baracos V., Rodeman P., Dinarello C.A., Goldberg A.L., Stimulation of muscle protein degradation and prostaglandin E2 release by leukocyte pyrogen (interleukin-1), N Engl J Med, 308, pp. 553-558, (1983)

← 1 2 3 →